Mylan v. Bausch Health: GC Receptor Patent Appeal Dismissed at Federal Circuit
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Mylan NV v. Bausch Health Ireland Ltd. |
| Case Number | Appeal No. 24-1011 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia |
| Duration | Oct 2023 – May 2025 593 days |
| Outcome | Voluntary Dismissal – No Precedent |
| Patents at Issue | |
| Accused Products | Generic Guanylate Cyclase Receptor Agonists |
Case Overview
The Parties
⚖️ Plaintiff
One of the world’s largest generic and specialty pharmaceutical manufacturers, with a history of challenging branded drug patents through ANDA filings.
🛡️ Defendant
Irish subsidiary of Bausch Health Companies Inc., a specialty pharmaceutical company with a significant branded drug portfolio in gastroenterology, dermatology, and ophthalmology.
Patents at Issue
This case involved one key patent covering guanylate cyclase receptor agonists and their therapeutic application in treating tissue inflammation and carcinogenesis:
- • US 7,041,786 B2 — Guanylate cyclase receptor agonists for tissue inflammation and carcinogenesis
Developing a similar therapeutic?
Check if your compound or method might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The appeal was **dismissed by stipulated agreement** on May 19, 2025. Each party bore its own costs, and no appellate precedent was established. This neutral cost arrangement typically signals a negotiated resolution.
Key Legal Issues
The case was an **Invalidity/Cancellation Action** where Mylan challenged the patentability of U.S. Patent No. 7,041,786 B2. Potential grounds included obviousness under 35 U.S.C. § 103, lack of enablement or written description under § 112, or anticipation under § 102. The dismissal means these underlying validity issues were not definitively ruled upon by the Federal Circuit, preserving the trial court’s record.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand invalidity challenges.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharma development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which pharma companies are most active in GC receptor IP
- Understand claim construction trends
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
Potential Infringement Risk
GC receptor agonists for inflammation/carcinogenesis
1 Patent at Issue
US 7,041,786 B2 (GC Receptor)
No Appellate Invalidity
Patent remains strong and enforceable
✅ Key Takeaways
For Patent Attorneys & Litigators
Voluntary Federal Circuit dismissals under Rule 42(b) preserve district-level outcomes and eliminate adverse appellate precedent risk.
Search related case law →US 7,041,786 B2 remains an active, enforceable patent — no invalidity finding was published.
Explore precedents →For R&D Teams & IP Professionals
GC-C receptor agonist development programs require current FTO clearance, as this dismissal does not invalidate US 7,041,786 B2.
Start FTO analysis for my product →For pharmaceutical patents, strong written description and enablement are crucial for broad method claims to withstand challenges.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.